Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Cyclophosphamide
  • Myelodysplastic Syndromes

abstract

  • These data suggest that the risk of secondary AML or MDS among patients with early breast cancer who receive standard-dose cyclophosphamide-containing adjuvant chemotherapy is not much higher than in the general population. However, physicians must remain alert to the possible long-term consequences of alkylating agent and anthracycline-based chemotherapy.

publication date

  • July 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7602344

Additional Document Info

start page

  • 1557

end page

  • 63

volume

  • 13

number

  • 7